Skip to content

EyePoint, Inc. EYPT Other Direct Research And Development Expense

Other Direct Research And Development Expense at other companies

Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$2.86M+3.1%
Tyra Biosciences, Inc. logo
Tyra Biosciences, Inc.TYRA
$849K+65.2%
Disc Medicine logo
Disc MedicineIRON
$2.17M+18.2%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$1.49M+25.5%
Zymeworks logo
ZymeworksZYME
$7.26M+19.6%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$7.98M+111%

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+108%
Enterprise value$1.15B+122%
P/S158.5×+148×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept eypt:OtherDirectResearchAndDevelopmentExpense.

The official record: EyePoint, Inc. ’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's other direct research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's other direct research and development expense?
EyePoint, Inc. (EYPT) reported other direct research and development expense of $759K in Q4 2025.
How has EyePoint, Inc. 's other direct research and development expense changed year-over-year?
EyePoint, Inc. 's other direct research and development expense increased by 14.3% year-over-year, from $664K to $759K.
What is the long-term trend for EyePoint, Inc. 's other direct research and development expense?
Over 2 years (2023 to 2025), EyePoint, Inc. 's other direct research and development expense has grown at a 106.2% compound annual growth rate (CAGR), from $714K to $3.04M.
What does other direct research and development expense mean?
Includes all research and development expenditures not allocated to the primary product platform, representing secondary pipeline investments. This metric highlights the breadth of the company's R&D portfolio beyond its flagship programs.